/THRD

THRD Stock - Third Harmonic Bio, Inc.

Q: What is the analyst price target for THRD?

Analyst price target information is not currently available for THRD.

Q: What is THRD's market cap?

Market capitalization information is not currently available for THRD.

Healthcare|Biotechnology|NASDAQ

$5.38-0.09%

$0.01 (-0.09%) • Aug 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+158.7%upside

Target: $13.92

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for THRD

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.13

52W High$16.02

52W Low$3.18

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-49,000	$-35,000	$-38,000	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$58.87M	$-43,954,000	$-37,708,000	$-19,004,000	$-11,119,000
Net Income	$45.47M	$-30,824,000	$-37,708,000	$-29,609,000	$-12,807,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$1.09	$-0.78	$-0.89	$-0.77	$-0.33

Company Overview

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

4 Bullish4 Neutral/Bearish

Price Targets

$16

Average Target

↑ 196.6% Upside

Now

Low

$16

Average

$34

High

Based on 9 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
March 28th 2025	Stifel	Downgrade	Hold	$5← $23
February 12th 2025	Morgan Stanley	Downgrade	Equal Weight	$5← $20
February 11th 2025	Raymond James	Downgrade	Market Perform	-
August 9th 2024	Morgan Stanley	Upgrade	Overweight	$20← $12
June 18th 2024	Stifel	Initiation	Buy	$23
June 7th 2024	Raymond James	Initiation	Outperform	$18
December 16th 2022	Jefferies	Downgrade	Hold	$3.6← $30
December 15th 2022	Morgan Stanley	Downgrade	Equal Weight	$5
October 10th 2022	Jefferies	Initiation	Buy	$30
October 10th 2022	Morgan Stanley	Initiation	Overweight	$34
October 10th 2022	Cowen	Initiation	Outperform	-

Earnings History & Surprises

THRD

Beat Rate

58%

Last 12 quarters

Avg Surprise

+18.8%

EPS vs Estimate

Beats / Misses

7/5

Last 12 quarters

Latest EPS

$-0.26

Q3 2025

EPS Surprise History

Q4 23

+51.3%

$-0.19vs$-0.39

Q1 24

+151.5%

$0.17vs$-0.33

Q2 24

+39.4%

$-0.20vs$-0.33

Q3 24

+10.3%

$-0.26vs$-0.29

Q4 24

-6.5%

$-0.33vs$-0.31

Q1 25

+19.4%

$-0.29vs$-0.36

Q2 25

-34.6%

$-0.35vs$-0.26

Q3 25

-18.2%

$-0.26vs$-0.22

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 14, 2025	$-0.22	$-0.26	-18.2%	✗ MISS
Q2 2025	May 8, 2025	$-0.26	$-0.35	-34.6%	✗ MISS
Q1 2025	Mar 27, 2025	$-0.36	$-0.29	+19.4%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.31	$-0.33	-6.5%	✗ MISS
Q3 2024	Aug 8, 2024	$-0.29	$-0.26	+10.3%	✓ BEAT
Q2 2024	May 15, 2024	$-0.33	$-0.20	+39.4%	✓ BEAT
Q1 2024	Mar 26, 2024	$-0.33	$0.17	+151.5%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.39	$-0.19	+51.3%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.49	$-0.19	+61.2%	✓ BEAT
Q2 2023	May 11, 2023	$-0.35	$-0.40	-14.3%	✗ MISS
Q1 2023	Mar 29, 2023	$-0.55	$-0.36	+34.5%	✓ BEAT
Q4 2022	Nov 9, 2022	$-0.41	$-0.69	-68.3%	✗ MISS
Q3 2022	Sep 15, 2022	—	$-0.30	—	—
Q2 2022	Jun 30, 2022	—	$-0.20	—	—
Q4 2021	Dec 31, 2021	—	$-0.60	—	—
Q3 2021	Sep 30, 2021	—	$-0.28	—	—
Q2 2021	Jun 30, 2021	—	$-0.82	—	—
Q1 2021	Mar 31, 2021	—	$-0.82	—	—

Frequently Asked Questions about THRD

What is THRD's current stock price?

Third Harmonic Bio, Inc. (THRD) is currently trading at $5.38 per share. The stock has moved -0.09% today.

What is the analyst price target for THRD?

The average analyst price target for THRD is $13.92, based on 1 analyst.

What sector is Third Harmonic Bio, Inc. in?

Third Harmonic Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is THRD's market cap?

Third Harmonic Bio, Inc. has a market capitalization of $0.24 billion, making it a small-cap company.

Does THRD pay dividends?

No, Third Harmonic Bio, Inc. does not currently pay a dividend to shareholders.